Fitch pointed to expected growth from drugs including Austedo and Ajovy; Teva is still rated below investment grade by S&P Global Ratings, at BB+ with a stable outlook, and by Moody’s, at Ba1 with a positive outlook Related TopicsFitch Ratings has upgraded Teva Pharmaceutical Industries’ corporate credit rating to investment grade, raising it to BBB- with a stable outlook from BB+. The announcement was made on Monday.The agency also upgraded Teva’s senior unsecured debt and credit facilities to BBB- from BB+.1 View gallery Teva headquarters in Israel(Photo: Sivan Farage)Teva said the move marks Fitch’s third upgrade of the company in less than two years. Chief Financial Officer Eli Kalif said the decision reflects confidence in Teva’s turnaround strategy and improving financial flexibility.Teva is still rated below investment grade by S&P Global Ratings, at BB+ with a stable outlook, and by Moody’s, at Ba1 with a positive outlook.Comments